Kovach J S, Hartmann A, Blaszyk H, Cunningham J, Schaid D, Sommer S S
Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1093-6. doi: 10.1073/pnas.93.3.1093.
Human cancer cells with a mutated p53 tumor-suppressor gene have a selective growth advantage and may exhibit resistance to ionizing radiation and certain chemotherapeutic agents. To examine the prognostic value of mutations in the p53 gene, a cohort of 90 Midwestern Caucasian breast cancer patients were analyzed with methodology that detects virtually 100% of all mutations. The presence of a p53 gene mutation was by far the single most predictive indicator for recurrence and death (relative risks of 4.7 and 23.2, respectively). Direct detection of p53 mutations had substantially greater prognostic value than immunohistochemical detection of p53 overexpression. Analysis of p53 gene mutations may permit identification of a subset of breast cancer patients who, despite lack of conventional indicators of poor prognosis, are at high risk of early recurrence and death.
携带p53肿瘤抑制基因突变的人类癌细胞具有选择性生长优势,并且可能对电离辐射和某些化疗药物表现出抗性。为了检验p53基因突变的预后价值,采用能检测几乎所有突变的方法,对一组90名来自美国中西部的白种人乳腺癌患者进行了分析。p53基因突变的存在是迄今为止复发和死亡的唯一最具预测性的指标(相对风险分别为4.7和23.2)。直接检测p53突变比免疫组化检测p53过表达具有更大的预后价值。对p53基因突变的分析可能有助于识别出一部分乳腺癌患者,这些患者尽管缺乏预后不良的传统指标,但早期复发和死亡风险很高。